|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
17.12(B) |
Last
Volume: |
1,235,787 |
Avg
Vol: |
1,397,134 |
52
Week Range: |
$76.22 - $100.3 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
658,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$62,013,572 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
58 |
End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-09-16 |
4 |
OE |
$12.99 |
$25,980 |
I/I |
2,000 |
50,740 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-09-10 |
4 |
A |
$70.06 |
$1,053 |
D/D |
15 |
68,732 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-09-09 |
4 |
AS |
$73.00 |
$1,460,000 |
D/D |
(20,000) |
62,262 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2013-09-09 |
4 |
OE |
$21.51 |
$430,200 |
D/D |
20,000 |
82,262 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-09-05 |
4 |
AS |
$70.00 |
$700,000 |
D/D |
(10,000) |
43,266 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-09-05 |
4 |
OE |
$11.05 |
$110,500 |
D/D |
10,000 |
53,266 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-09-04 |
4 |
AS |
$69.00 |
$621,000 |
D/D |
(9,000) |
37,950 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-09-04 |
4 |
OE |
$39.06 |
$351,540 |
D/D |
9,000 |
46,950 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-08-15 |
4 |
S |
$64.36 |
$64,364 |
I/I |
(1,000) |
48,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-08-15 |
4 |
OE |
$12.99 |
$12,990 |
I/I |
1,000 |
49,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-07-15 |
4 |
OE |
$63.70 |
$63,698 |
I/I |
1,000 |
48,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-07-15 |
4 |
OE |
$12.99 |
$12,990 |
I/I |
1,000 |
49,740 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-07-01 |
4 |
AS |
$59.56 |
$243,063 |
D/D |
(4,066) |
37,950 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-07-01 |
4 |
AS |
$60.00 |
$600,000 |
D/D |
(10,000) |
43,266 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-07-01 |
4 |
OE |
$11.05 |
$110,500 |
D/D |
10,000 |
53,266 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2013-06-19 |
4 |
A |
$58.57 |
$1,057 |
D/D |
18 |
68,717 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-06-12 |
4 |
OE |
$12.99 |
$64,950 |
I/I |
5,000 |
48,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-06-05 |
4 |
OE |
$58.68 |
$593,406 |
I/I |
10,000 |
43,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-06-05 |
4 |
OE |
$12.99 |
$129,900 |
I/I |
10,000 |
53,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-06-04 |
4 |
OE |
$60.72 |
$607,194 |
I/I |
10,000 |
43,740 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2013-06-04 |
4 |
OE |
$12.99 |
$129,900 |
I/I |
10,000 |
53,740 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2013-06-03 |
4 |
AS |
$58.32 |
$64,036 |
D/D |
(1,098) |
43,266 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-06-03 |
4 |
AS |
$58.34 |
$28,763 |
D/D |
(493) |
14,880 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2013-05-31 |
4 |
D |
$62.70 |
$25,895 |
D/D |
(413) |
8,447 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2013-05-31 |
4 |
D |
$62.70 |
$18,622 |
D/D |
(297) |
15,373 |
|
- |
|
1335 Records found
|
|
Page 9 of 54 |
|
|